Board of Directors

Mano Thubrikar, PhD, FAHA, President & Founder

Deodatt Wadke, PhD, Co-Founder

Dr. Wadke is a retired pharmaceutical executive with over 40 years of R&D and regulatory experience. He began his career in the pharmaceutical industry in 1966 when he joined Merck, Sharp & Dohme as a Research Associate and worked in the Exploratory Research Section of the Pharmaceutical Development Department. He moved to Squibb (now Bristol-Myers Squibb) in 1969 and elected to retire in January 1994 as Director of Pharmaceuticals R&D, New Brunswick site. As Director, Dr. Wadke was responsible for the physico-chemical characterization of new chemical entities, development of oral solid and parenteral products from conception to plant introduction, the manufacture and packaging of phase I-IV clinical supplies, and the generation of technical data packages for the U.S. and overseas regulatory filings. He is familiar with contemporary cGMP requirements, including those for pharmaceutical manufacturing and testing operations. Since his retirement from BMS, Dr. Wadke has worked as a consultant to the pharmaceutical industry in the areas of product development and regulatory compliance serving PhRMA, generic and start-up companies in the U.S. and overseas. He has published various articles in peer-reviewed journals and has served as an adjunct professor at Long Island University. He holds a Ph.D. in Chemistry from the State University of New York at Buffalo, an M.S. in Physical Pharmacy from Ohio State University, and a B.S. in Pharmacy from Banaras Hindu University.

Sachin Parate, BS, CFA, Principal Investor

Mr. Parate has been a Partner/Owner of a proprietary trading desk specializing in arbitrage opportunities since 2002. He began his career in 1994 at Susquehanna International Group for whom he traded equity derivatives as a market maker, specialist, and lead market maker on the Philadelphia Stock Exchange and Pacific Stock Exchange. He has also built a portfolio of public equity, real estate investments, as well as private debt and equity including Thubrikar Aortic Valve, Inc. He holds a B.S. in Economics with a concentration in Finance from the Wharton School of the University of Pennsylvania.

Tony Zhu, MBA, MBBS, License Partner

Dr. Zhu is the President and Founder of CCRF, a leading Contract Research Organization (CRO) for medical devices focused on interventional cardiology in China.  Wide Line Limited is the main shareholder of CCRF. He has over 20 years of sales, marketing, and management experience in the medical device industry, with specialties in Interventional Cardiovascular, Electrophysiology, and Cardiac Rhythm Management. He has also co-founded start-up companies for interventional cardiology devices and serves as a Board Member to multiple medical companies. Dr. Zhu practiced as a physician specialist in Microbiology and Immunology from 1992-1996, and began his business career in the medical industry in 1996 when he joined Ethicon Wound Closure, Johnson & Johnson Medical, China. He holds an MBBS from the School of Medicine, Shanghai Jiao Tong University, China, and an MBA from Lord Ashcroft International Business School, Anglia Ruskin University, UK.